Key clinical point: Patients with psoriatic arthritis (PsA) reported musculoskeletal pain as the most burdensome symptom and preferred a treatment regimen that improved their joint symptoms and did not include a methotrexate coprescription.
Major finding: J oint pain (98%), fatigue (94%), and morning stiffness (94%) were the most common symptoms of PsA; therefore, 74% of patients preferred therapies that improved joint-related vs. psoriasis-related symptoms, with once-daily oral medication being preferred by 38% of patients and 47% of patients with experience receiving methotrexate preferring a treatment regimen without methotrexate.
Study details: This cross-sectional, web-based survey included 332 adults from ArthritisPower who had a self-reported physician diagnosis of PsA.
Disclosures: This study was funded by AbbVie and RTI Health Solutions. Three authors declared being employees of RTI Health Solutions, two authors declared being employees or share/stockowners of AbbVie, and other authors declared financial/nonfinancial ties with various sources.
Source: Ogdie A et al. Experiences and treatment preferences in patients with psoriatic arthritis: A cross-sectional study in the ArthritisPower registry. Rheumatol Ther. 2022 (Mar 13). Doi: 10.1007/s40744-022-00436-x